
Topic
Payer Policy
Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.

Policy· July 17, 2026 · 18 min read

Pricing & Access· July 16, 2026 · 23 min read
Atopic dermatitis systemic access: Dupixent, JAK inhibitors, and biologics

Policy· July 16, 2026 · 24 min read
Companion diagnostic change control: FDA PMA supplement vs. EU IVDR
By Ran Chen#Companion Diagnostic#FDA Approval#EMA

Pipeline· July 16, 2026 · 22 min read
Digital health endpoints in FDA trials and the payer handoff gap
By Ran Chen#Clinical Trials#Payer Policy#FDA

Pricing & Access· July 14, 2026 · 18 min read
Generalized Myasthenia Gravis (gMG) Access and Dosing Landscape
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding

Pricing & Access· July 14, 2026 · 20 min read
PNH Access Landscape: C5 Blockers, Orals, and the Biosimilar Cliff
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding

Specialty· July 9, 2026 · 17 min read
IgA Nephropathy Access: Trutakna, Filspari, Tarpeyo, Fabhalta, and Voyxact

Pricing & Access· July 8, 2026 · 22 min read
Gilead Sciences Portfolio Dossier: The Biktarvy Cliff, Yeztugo PrEP, and an Oncology Reset
By Ran Chen#HIV PrEP#Generic Entry#Drug Pricing

Specialty· July 7, 2026 · 21 min read
Voranigo (vorasidenib) Glioma Access: Pricing, Biomarker Testing, and Payer PA
By Ran Chen#Oncology#Orphan Drug#Prior Authorization

Pricing & Access· July 5, 2026 · 16 min read